Board of Directors

The Board's experience and skills are complimentary and diverse, bringing together commercial, scientific, medical and legal expertise.

Dr John Chiplin BPharm PhD

Non-Executive Director

Dr Chiplin has broad-based experience in the life science and technology industries, both from an operational and investment perspective.  His most recent accomplishment was the corporate reengineering of Arana Therapeutics, a world leading Antibody developer, which resulted in the acquisition of the company by Cephalon for a significant premium to market (July 2009).  Immediately prior to running Arana, Dr. Chiplin was head of the $300M ITI Life Sciences investment fund in the UK.  His own investment vehicle, Newstar Ventures Ltd, has funded more than a dozen early stage companies in the past ten years.  Dr. Chiplin's Pharmacy & Doctoral degrees are from the University Of Nottingham, UK.  In addition to Progen, John currently serves on the boards of Benitec Ltd, Sciencemedia, and Velocity Partners LLC.

Mr Stuart James BA Honours

Chairman

Mr. James has held a number of high profile executive positions during his career and has extensive experience in the oil, health and financial services sector.  Following a 25 year career with Shell both in Australia and internationally, Mr. James past roles have included Managing Director of Australian Financial Services for Colonial and Managing Director of Colonial State Bank (formally the State Bank of N.S.W).  Mr. James most recent executive role was a C.E.O of The Mayne Group, including Mayne Health and Mayne Pharma.  He is a Member of the Supervisory Board of Wolters Kluwer NV  and a member of the Advisory Board of Gresham Private Equity Ltd.  Mr, James is Chairman of Pulse Health Ltd., Prime Financial Group Ltd and a Non Executive Director of Greencross Ltd. 

Dr Julie Cherrington BS MS PhD

Non-Executive Director

Julie Cherrington joined Pathway Therapeutics as President and CEO in Oct 2009.  Previously, Dr. Cherrington was president at Phenomix Corporation with strategic and operational responsibilities for drug research and development at the discovery, pre-clinical and clinical stages, and played a leadership role in the financing, business development and corporate development functions in the company.  Prior to joining Phenomix in 2003, she was vice president of pre-clinical and clinical research at SUGEN, a Pfizer company.  SUGEN focused on the discovery and development of small molecule kinase inhibitors for cancer and was a leader in molecular profiling patient samples in concert with innovative Phase 1 and Phase 2 clinical trial designs with novel targeted agents.  Dr. Cherrington was instrumental in the development of SUTENT and its approval for renal cell cancer and gastrointestinal stromal tumors.  Prior to SUGEN, Dr. Cherrington held a range of positions of increasing responsibility at Gilead Sciences.  Dr. Cherrington is currently a member of the Board of Directors of Progen Pharmaceuticals, an oncology biotechnology company, and Xenome Ltd, a pain focused biotechnology company.

Mr Heng Hsin Tang BENG(Hons) MBA

Non-Executive Director

Mr Tang has a bachelor’s degree in Civil Engineering with honours, and an MBA from the University of Queensland. Mr Tang has more than 10 years experience in project and financial managements in engineering and property development, specialising in feasibility studies, cash-flow management, structural finance and acquisitions for major projects. Until recently, Mr Tang was Commercial Manager for a national property developer, and managed the finance for their Queensland projects valued at over $1bn.